Estimates suggest that HIV incidence rates in Eswatini have fallen in recent years, as significant progress has been made in improving the number of people receiving antiretroviral (ARV) treatment.
We continue to help more HIV patients access ARV treatment through the ’test and start’ strategy. A team has been piloting ‘test and start’ in the Nhlangano project; after HIV testing, ARV treatment was offered to more than 1,700 people after a positive HIV diagnosis to immediately start treatment.
We now treat patients with extensively drug-resistant TB (XDR-TB), and those developing severe side effects, using the promising new drugs bedaquiline and delamanid in combination with repurposed drugs.
Our activities in 2022 in Eswatini
Data and information from the International Activity Report 2022.
123
123
€4.7 M
4.7M
2007
2007


6,620
6,62
690
69
140
14

Pharmaceutical company ViiV must provide transparency on HIV prevention drug

Ravaged by new strain, southern Africa must get COVID-19 vaccines

Eswatini: Responding to COVID-19 in a country already fighting a dual HIV/TB epidemic

AIDS death toll stagnating due to lack of testing at community level

MSF report "No time to lose" examines the fight against AIDS in 15 countries
